Help us protect Maryland patients, critical life sciences jobs, and innovation
Maryland's life sciences industry is a national leader in life sciences and technology innovation. Companies, organizations, and universities across the state work around the clock to research, develop, and test treatments that transform `lives.
As Maryland's Prescription Drug Affordability Board (PDAB) prepares to deliver recommendations on lowering prescription drug costs for patients, and lawmakers seek to expand authority of the PDAB, it's critical that any policies that Maryland lawmakers consider to lower drug prices do not come at the expense of our state's robust life sciences ecosystem.
Help us protect Maryland patients, critical life sciences jobs, and innovation.
Join us today and send a letter to Maryland lawmakers encouraging them to protect patient access to new and innovative treatments by supporting our local biotechnology industry. Maryland lawmakers must support proposals to lower health care costs that do not unintentionally hinder critical innovation, research, and development happening here in Maryland.
Sign PetitionSign Petition
As your constituent, I urge you to support and advance policies that protect Maryland patients and life sciences jobs across the state. Maryland is a national leader in life sciences and technology innovation. Our state is home to over 2,700 life sciences firms, more than 500 biotechnology companies, and 74 federal research labs, including the National Institutes of Health (NIH) and the Food and Drug Administration (FDA).
As Maryland's Prescription Drug Affordability Board (PDAB) prepares to deliver recommendations on lowering prescription drug costs for patients and several lawmakers seek to expand authority of the PDAB this session, legislators must ensure that any proposed legislation does not come at the expense of patient access to innovative treatments and Maryland's ability to research, test, and develop new treatments and therapies for patients in the state and beyond.
It is critical that the legislature takes action to protect the over 54,000 Marylanders employed by the life sciences industry who work around the clock to develop new treatments for patients in need. SB0388 and HB0340 risk weakening Maryland's ability to innovate, research, develop, and bring to market new treatments and cures for patients. I urge you to stand with Maryland's innovation ecosystem and patients living with chronic and debilitating conditions by opposing these bills.